SpringWorks Therapeutics, Inc. (SWTX)
Jul 1, 2025 - SWTX was delisted (reason: acquired by Merck KGaA)
46.99
0.00 (0.00%)
Inactive · Last trade price on Jun 30, 2025
SpringWorks Therapeutics Stock Forecast
Stock Price Forecast
The 7 analysts with 12-month price forecasts for SpringWorks Therapeutics stock had an average target of 56.86, with a low estimate of 47 and a high estimate of 77.
Price Target: $56.86 (+21%)
Analyst Consensus: Buy
* Price targets were last updated on May 12, 2025.
Analyst Ratings
The average analyst rating for SpringWorks Therapeutics stock from 7 stock analysts was "Buy". This means that analysts believed this stock was likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 0 | 0 | 0 |
| Buy | 4 | 4 | 4 | 3 | 3 | 3 |
| Hold | 0 | 0 | 0 | 4 | 4 | 4 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 7 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Guggenheim | Guggenheim | Hold Reiterates $47 | Hold | Reiterates | $47 | +0.02% | May 12, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy → Hold Downgrades $74 → $47 | Strong Buy → Hold | Downgrades | $74 → $47 | +0.02% | Apr 30, 2025 |
| Guggenheim | Guggenheim | Strong Buy → Hold Downgrades $77 → $47 | Strong Buy → Hold | Downgrades | $77 → $47 | +0.02% | Apr 29, 2025 |
| TD Cowen | TD Cowen | Strong Buy → Hold Downgrades $66 → $47 | Strong Buy → Hold | Downgrades | $66 → $47 | +0.02% | Apr 29, 2025 |
| Barclays | Barclays | Buy → Hold Downgrades $63 → $47 | Buy → Hold | Downgrades | $63 → $47 | +0.02% | Apr 28, 2025 |
Financial Forecast
Revenue This Year
334.05M
from 191.59M
Increased by 74.36%
Revenue Next Year
586.68M
from 334.05M
Increased by 75.63%
EPS This Year
-2.81
from -3.48
EPS Next Year
-1.51
from -2.81
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 417.5M | 753.1M | 1.2B | ||
| Avg | 334.1M | 586.7M | 805.9M | ||
| Low | 269.4M | 435.0M | 630.1M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 117.9% | 125.4% | 102.5% | ||
| Avg | 74.4% | 75.6% | 37.4% | ||
| Low | 40.6% | 30.2% | 7.4% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.59 | -0.23 | 3.05 | ||
| Avg | -2.81 | -1.51 | 1.21 | ||
| Low | -4.08 | -2.69 | -0.43 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.